Floatz Rating
B58/100
Confidence
Indicative
Sponsor
The Third Affiliated hospital of Zhejiang Chinese Medical University
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06737549CT.gov Effect of Specific Mode Electroacupuncture Stimulation Combined with NGF on Dysphagia After Ischaemic Stroke: a Pilot Randomized Controlled Trial | — | Recruiting | — | — | — |
NCT05231694CT.gov The Impact of Electroacupuncture Combined With NGF on Clinical Effect and Functional Changes on Ischemic Stroke | — | Unknown | — | — | — |
NCT05652751CT.gov Effect of EA Combined With NGF on Limb Function in Convalescent Patients With Ischemic Stroke | — | Unknown | — | — | — |
NCT03686163CT.gov Effects of Intranasal Nerve Growth Factor for Acute Ischemic Stroke | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ischemic Stroke
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nerve Growth Factor (this asset) | The Third Affiliated hospital of Zhejiang Chinese Medical University | Approved | B · 58 |
| Ticagrelor | Sichuan Provincial People's Hospital | P4 | BBB |
| Cilostazol | Stanford University | P4 | BBB |
| Compound Edaravone | Nanfang Hospital, Southern Medical University | P4 | BBB |
| 3-N-BUTYLPHTHALIDE | Nanfang Hospital, Southern Medical University | P4 | BBB |
| Argatroban | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Tenecteplase | Hackensack Meridian Health | P4 | BBB |
| Clopidogrel | Nanfang Hospital, Southern Medical University | P4 | BB |
| Aspirin | Nanfang Hospital, Southern Medical University | P4 | BB |
+42 more in the Ischemic Stroke cohort
Other indications for Nerve Growth Factor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Traumatic Brain Injury | — | P2 | CCC · 54 |
| Amyotrophic Lateral Sclerosis | — | P2/3 | CCC · 52 |
| Alzheimer Disease | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nerve Growth Factor in Ischemic Stroke. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nerve-growth-factor-ischemic-stroke
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →